Literature DB >> 34180244

Lower In-Hospital Mortality With Beta-Blocker Use at Admission in Patients With Acute Decompensated Heart Failure.

Yodo Tamaki1, Hidenori Yaku2, Takeshi Morimoto3, Yasutaka Inuzuka4, Neiko Ozasa5, Erika Yamamoto5, Yusuke Yoshikawa5, Makoto Miyake1, Hirokazu Kondo1, Toshihiro Tamura1, Takeshi Kitai6, Moritake Iguchi7, Kazuya Nagao8, Ryusuke Nishikawa9, Yuichi Kawase10, Takashi Morinaga11, Mitsunori Kawato12, Mamoru Toyofuku13, Yukihito Sato14, Koichiro Kuwahara15, Yoshihisa Nakagawa16, Takao Kato5, Takeshi Kimura5.   

Abstract

Background It remains unclear whether beta-blocker use at hospital admission is associated with better in-hospital outcomes in patients with acute decompensated heart failure. Methods and Results We evaluated the factors independently associated with beta-blocker use at admission, and the effect of beta-blocker use at admission on in-hospital mortality in 3817 patients with acute decompensated heart failure enrolled in the Kyoto Congestive Heart Failure registry. There were 1512 patients (39.7%) receiving, and 2305 patients (60.3%) not receiving beta-blockers at admission for the index acute decompensated heart failure hospitalization. Factors independently associated with beta-blocker use at admission were previous heart failure hospitalization, history of myocardial infarction, atrial fibrillation, cardiomyopathy, and estimated glomerular filtration rate <30 mL/min per 1.73 m2. Factors independently associated with no beta-blocker use were asthma, chronic obstructive pulmonary disease, lower body mass index, dementia, older age, and left ventricular ejection fraction <40%. Patients on beta-blockers had significantly lower in-hospital mortality rates (4.4% versus 7.6%, P<0.001). Even after adjusting for confounders, beta-blocker use at admission remained significantly associated with lower in-hospital mortality risk (odds ratio, 0.41; 95% CI, 0.27-0.60, P<0.001). Furthermore, beta-blocker use at admission was significantly associated with both lower cardiovascular mortality risk and lower noncardiovascular mortality risk. The association of beta-blocker use with lower in-hospital mortality risk was relatively more prominent in patients receiving high dose beta-blockers. The magnitude of the effect of beta-blocker use was greater in patients with previous heart failure hospitalization than in patients without (P for interaction 0.04). Conclusions Beta-blocker use at admission was associated with lower in-hospital mortality in patients with acute decompensated heart failure. Registration URL: https://www.upload.umin.ac.jp/; Unique identifier: UMIN000015238.

Entities:  

Keywords:  acute decompensated heart failure; beta‐blocker; cohort study

Year:  2021        PMID: 34180244     DOI: 10.1161/JAHA.120.020012

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  2 in total

Review 1.  Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction.

Authors:  John W Ostrominski; Muthiah Vaduganathan
Journal:  Clin Cardiol       Date:  2022-06       Impact factor: 3.287

2.  Association Between Early Oral β-Blocker Therapy and In-Hospital Outcomes in Patients With ST-Elevation Myocardial Infarction With Mild-Moderate Heart Failure: Findings From the CCC-ACS Project.

Authors:  Miao Wang; Jing Liu; Jun Liu; Yongchen Hao; Na Yang; Tong Liu; Sidney C Smith; Yong Huo; Gregg C Fonarow; Junbo Ge; Louise Morgan; Changsheng Ma; Yaling Han; Dong Zhao; Siyan Zhan
Journal:  Front Cardiovasc Med       Date:  2022-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.